secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0000875320-24-000231
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year
--------------------------------------------------------------------------------

- FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.
- Annual wholesale acquisition cost in the U.S. is $370,269 ($28,404 per 28-day pack).
- Approval expands Vertex's cystic fibrosis treatment portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/0000875320-24-000231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532024000231/vrtx-20241220.htm
  HTML page:      https://secwatch.observer/filing/0000875320-24-000231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer